bigger Created with Sketch.

News & Events

News & Events

To sign up for news alerts, please e-mail info@homologymedicines.com

For media inquiries, please email cmayfield@homologymedicines.com

News
& Events

06/04/2018
Homology Medicines Convenes Panel on Developing Genetic Medicines for Patients at BIO International Convention​
05/18/2018
Homology Medicines Presents Data from PKU Gene Therapy Program Demonstrating Long-Term Durability of Treatment in IND-Enabling Studies​
05/14/2018
Homology Medicines Reports First Quarter 2018 Financial Results​
05/10/2018
Homology Medicines Receives Award for Revolutionary New Therapeutic or Platform Startup from New England Venture Capital Association​
05/10/2018
Homology Medicines to Present at Bank of America Merrill Lynch Healthcare Conference​
05/01/2018
Homology Medicines Recognizes PKU Awareness Month​
04/30/2018
Homology Medicines Announces Upcoming Presentations on its Genetic Medicines Platform at the American Society of Gene & Cell Therapy Meeting​
04/23/2018
Homology Medicines to Participate in the World Orphan Drug Congress​
04/03/2018
Homology Medicines Announces Closing of Initial Public Offering​
03/27/2018
Homology Medicines Announces Pricing of Initial Public Offering​
03/15/2018
Homology Medicines Appoints Mary Thistle to Board of Directors​
03/01/2018
Homology Medicines Announces Peer-Reviewed Publication Indicating Low Prevalence of Pre-existing Neutralizing Antibodies to its Human-Derived AAVHSC Vectors​
02/28/2018
Homology Medicines Recognizes Rare Disease Day with Messages to the Patient Community​
01/22/2018
Homology Medicines to Participate in Gene Editing Panel at Cell & Gene Therapy World Conference​
01/17/2018
Homology Medicines Appoints Matthew R. Patterson to Board of Directors​
11/13/2017
Homology Medicines and Novartis Enter Collaboration to Develop New Treatments Using Homology’s Proprietary Gene Editing Technology​
10/03/2017
Homology Medicines to Present at the Cell & Gene Meeting on the Mesa​
08/01/2017
Homology Medicines Announces $83.5 Million Series B Financing to Advance Lead Development Candidate and AMEnDR™ In Vivo Gene Editing Technology ​
06/19/2017
Homology Medicines to Participate in Panel on Genetic Medicines at 2017 BIO International Convention​
05/31/2017
Homology Medicines Strengthens Manufacturing and Product Development Expertise with Appointment of Tim Kelly as Senior Vice President, Technical Operations​
05/15/2017
Homology Medicines Presents Data Demonstrating Highly Efficient, On-Target In Vivo Gene Editing Capabilities of its Novel Human-Derived Adeno-Associated Virus Vectors​
04/24/2017
Homology Medicines Announces Four Presentations on its Gene Editing and Gene Therapy Platform at the American Society of Gene & Cell Therapy Meeting​
04/20/2017
Homology Medicines to Present at the Alliance for Regenerative Medicine’s Cell & Gene Therapy Investor Day​
04/04/2017
Homology Medicines Appoints Brad Smith as Chief Financial Officer​
01/03/2017
Homology Named Top 20 Life Science Startups to Watch in 2017​
11/01/2016
Homology Medicines Featured in PharmaVoice's Trending 2017: Gene Editing​
09/15/2016
Homology Medicines Acquires License to Novel AAV Technology to Develop Treatments for Central Nervous System Disorders​
05/02/2016
Homology Medicines Emerges with Next Generation Gene Editing Technology Driven by Industry-leading Team in Rare Diseases​